Edition:
United States

McKesson Corp (MCK)

MCK on New York Consolidated

145.40USD
6 Dec 2016
Change (% chg)

-- (--)
Prev Close
$145.40
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,282,154
52-wk High
$202.20
52-wk Low
$114.53

Select another date:

Sun, Nov 13 2016

BRIEF-Medical Developments International says Trump's election will not negatively impact co

* Mckesson placed its first order for stock which will be delivered by end of december

U.S. drug wholesaler shares tumble on pricing-war fears

NEW YORK Shares of the three major U.S. prescription drug wholesalers tumbled on Friday as investors feared a pricing war after McKesson Corp's quarterly report that rippled through the pharmaceutical supply chain.

U.S. drug wholesaler shares tumble on pricing-war fears

NEW YORK, Oct 28 Shares of the three major U.S. prescription drug wholesalers tumbled on Friday as investors feared a pricing war after McKesson Corp's quarterly report that rippled through the pharmaceutical supply chain.

BRIEF-McKesson sets regular quarterly dividend of $0.28per share

* Sets regular quarterly dividend of $0.28per share Source text for Eikon: Further company coverage:

BRIEF-Varian and McKesson Specialty Health announces strategic agreement

* Varian and McKesson Specialty Health announce strategic agreement for advanced radiotherapy equipment and software Source text for Eikon: Further company coverage:

German antitrust watchdog raids drugs distributors

FRANKFURT, Sept 15 Germany's antitrust regulator raided eight drug wholesale companies, including a subsidiary of U.S. healthcare services provider McKesson Corp, on suspicion of illegal collusion.

BRIEF-Mckesson received request from U.S. DOJ pursuant to Hart-Scott-Rodino Antitrust improvements act

* Received a request for additional information and documentary material from u.s. Doj pursuant to hart-scott-rodino antitrust improvements act

BRIEF-Mckesson Q1 GAAP EPS $2.88 from continuing operations

* Fy2017 earnings per share view $13.64 -- Thomson Reuters I/B/E/S

BRIEF-UK's CMA says not refer Mckesson unit, AAH Pharma-UDG deal for phase 2 probe

* UK's CMA says decided not to refer merger by Mckesson Corp unit AAH Pharmaceuticals of MASTA and Sangers to a Phase 2 investigation. Source text for Eikon: (http://bit.ly/29eSv3J) (Bengaluru Newsroom)

McKesson's IT unit to merge with Change Healthcare

Healthcare services provider McKesson Corp said it would combine most of its information technology business with Change Healthcare Holdings Inc to form a new company with combined pro forma annual revenue of $3.4 billion.

Select another date: